We previously demonstrated that tofacitinib was effective in treating skin-predominant refractory dermatomyositis (DM) at 12 weeks in a prospective open label clinical trial, Study of Tofacitinib In Refractory dermatomyositis (STIR) (1). Here, we report the long-term extension results of up to 96 weeks to investigate the treatment durability of tofacitinib in refractory DM. Inclusion criteria and outcome measures were the same as the parent study (1). Assessments were conducted at weeks 20, 72, and 96. The baseline demographic features of all 10 trial patients were reported previously (1).

中文翻译：

---

托法替尼治疗难治性皮肌炎的长期扩展研究

我们之前在一项前瞻性开放标签临床试验（T ofacitinib I n R难治性皮肌炎 (STIR) 研究）中证明，托法替尼可有效治疗 12 周时以皮肤为主的难治性皮肌炎 (DM) (1 ) 。在这里，我们报告了长达 96 周的长期延长结果，以研究托法替尼在难治性 DM 中的治疗持久性。纳入标准和结果测量与父研究 (1) 相同。在第 20 周、第 72 周和第 96 周进行了评估。所有 10 名试验患者的基线人口统计学特征均已在之前报告过 (1)。